← Leaderboards
Afamefuna Okoye
Henry M. Jackson Fdn For The Adv Mil/Med
$9,317,654
Attributed
$15,339,845
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.3M · FY2015–25$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,339,845 · 6
By mechanism
R01$14,619,938 · 4
R21$719,907 · 2
Top collaborators
- Lydie Trautmann7 shared
- Lishomwa C Ndhlovu4 shared
- Christopher W Peterson2 shared
- Nicolas Chomont1 shared
- Timothy Jensen Henrich1 shared
- Henry F. Vanbrocklin1 shared
Most similar at Henry M. Jackson Fdn For The Adv Mil/Med
Same institution · by research overlap
- Mark G. Lewis$2,495,135
- Clifford M Snapper$6,968,557
- Joseph John Mattapallil$4,666,023
- Sandhya Vasan$13,271,172
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DoseHiv InfectionsMediatingImmuneMacaca MulattaAntiretroviral TherapyBloodViralInfectionT Cell ResponseAntigensAcuteCd8-Positive T-LymphocytesViral ReservoirVirusDisease RemissionPreventSpecificityCellsImmune ResponseLymphoid TissueB-LymphocytesNonhuman PrimateIn Vitro
Grant awards (17)
Multimodal PET-CT imaging of SIVmac239 dynamics post-ART interruption$3,302,677
R01 · FY2025 · AI · contact PI
Impact of IL-15 immunotherapy on tissue-specific CD8 T cells to reduce the CNS HIV reservoir seeding and persistence$974,060
R01 · FY2025 · MH
Impact of IL-15 immunotherapy on tissue-specific CD8 T cells to reduce the CNS HIV reservoir seeding and persistence$975,768
R01 · FY2024 · MH
Development of an mRNA-Based Therapeutic HIV/AIDS Vaccine$827,328
R01 · FY2024 · AI · contact PI
Impact of IL-15 immunotherapy on tissue-specific CD8 T cells to reduce the CNS HIV reservoir seeding and persistence$974,407
R01 · FY2023 · MH
Targeting the HIV/SIV reservoir at time of ART initiation$841,447
R01 · FY2023 · AI · contact PI
Development of an mRNA-Based Therapeutic HIV/AIDS Vaccine$840,477
R01 · FY2023 · AI · contact PI
Optimizing the Depletion of innate immune Effector Cells in Nonhuman Primates$205,403
R21 · FY2023 · AI · contact PI
Impact of IL-15 immunotherapy on tissue-specific CD8 T cells to reduce the CNS HIV reservoir seeding and persistence$1,165,864
R01 · FY2022 · MH
Development of an mRNA-Based Therapeutic HIV/AIDS Vaccine$823,817
R01 · FY2022 · AI · contact PI
Targeting the HIV/SIV reservoir at time of ART initiation$814,441
R01 · FY2022 · AI · contact PI
Optimizing the Depletion of innate immune Effector Cells in Nonhuman Primates$265,654
R21 · FY2022 · AI · contact PI
Development of an mRNA-Based Therapeutic HIV/AIDS Vaccine$844,491
R01 · FY2021 · AI · contact PI
Targeting the HIV/SIV reservoir at time of ART initiation$696,598
R01 · FY2021 · AI · contact PI
Development of an mRNA-Based Therapeutic HIV/AIDS Vaccine$850,670
R01 · FY2020 · AI · contact PI
Targeting the HIV/SIV reservoir at time of ART initiation$687,893
R01 · FY2020 · AI · contact PI
Purging the latent HIV reservoir at ART inititation: A new eradication strategy$248,850
R21 · FY2015 · AI